GPIHBP1 Antibody

Code CSB-PA811603LA01HU
Size US$166
Order now
Image
  • Western Blot
    Positive WB detected in: Rat liver tissue, Mouse heart tissue, Mouse lung tissue, Mouse kidney tissue
    All lanes: GPIHBP1 antibody at 4μg/ml
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 20 kDa
    Observed band size: 20 kDa

  • Immunohistochemistry of paraffin-embedded human skin tissue using CSB-PA811603LA01HU at dilution of 1:100

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) GPIHBP1 Polyclonal antibody
Uniprot No.
Target Names
GPIHBP1
Alternative Names
GPIHBP1; HBP1; Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1; GPI-HBP1; GPI-anchored HDL-binding protein 1; High density lipoprotein-binding protein 1
Raised in
Rabbit
Species Reactivity
Human, Mouse, Rat
Immunogen
Recombinant Human Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 protein (21-151AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The GPIHBP1 Antibody (Product code: CSB-PA811603LA01HU) is Non-conjugated. For GPIHBP1 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA811603LB01HU GPIHBP1 Antibody, HRP conjugated ELISA
FITC CSB-PA811603LC01HU GPIHBP1 Antibody, FITC conjugated
Biotin CSB-PA811603LD01HU GPIHBP1 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, WB, IHC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

The GPIHBP1 antibody was derived from the rabbits immunized with the recombinant human GPIHBP1 protein (21-151aa). This rabbit anti-human GPIHBP1 polyclonal antibody was tested to detect human, mouse, and rat GPIHBP1 proteins in ELISA, IHC, and WB applications. The non-conjugated IgG got purified by protein G and reached up to 95% in purity.

The target protein GPIHBP1 is essential for the proper functioning of lipoprotein lipase (LPL), allowing LPL to efficiently break down triglycerides in circulating lipoproteins, such as chylomicrons and very-low-density lipoproteins (VLDLs), and to release free fatty acids for use by the body. This process facilitates efficient triglyceride metabolism and helps maintain healthy lipid levels in the bloodstream. Defects or mutations in GPIHBP1 have been linked to familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by severe hypertriglyceridemia due to impaired LPL activity.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Mediates the transport of lipoprotein lipase LPL from the basolateral to the apical surface of endothelial cells in capillaries. Anchors LPL on the surface of endothelial cells in the lumen of blood capillaries. Protects LPL against loss of activity, and against ANGPTL4-mediated unfolding. Thereby, plays an important role in lipolytic processing of chylomicrons by LPL, triglyceride metabolism and lipid homeostasis. Binds chylomicrons and phospholipid particles that contain APOA5. Binds high-density lipoprotein (HDL) and plays a role in the uptake of lipids from HDL.
Gene References into Functions
  1. the negatively charged IDR of GPIHBP1 traverses a vast space, facilitating capture of LPL by capillary endothelial cells and simultaneously contributing to GPIHBP1's ability to preserve LPL structure and activity. PMID: 29899144
  2. The increased GPIHBP1 was significantly associated with decreased body weight. PMID: 29056530
  3. apoC-III potently inhibits triglyceride hydrolysis when LPL is bound to GPIHBP1 PMID: 28694296
  4. mutation of a conserved cysteine in GPIHBP1 abolishes the ability of GPIHBP1 to bind LPL PMID: 28476858
  5. One of 33 patients with unexplained chylomicronemia had the GPIHBP1 autoantibody syndrome PMID: 28666713
  6. Triglyceride-raising variant alleles of the GPIHBP1, encoding glycosylphosphatidylinositol-anchored HDL-binding protein 1,associated with clinical Cardiovascular endpoints. PMID: 28534127
  7. The authors now show: (1) that ANGPTL4 inactivates LPL by catalyzing the unfolding of its hydrolase domain; (2) that binding to GPIHBP1 renders LPL largely refractory to this inhibition; and (3) that both the LU domain and the intrinsically disordered acidic domain of GPIHBP1 are required for this protective effect. PMID: 27929370
  8. familial chylomicronemia due to mutations in GPIHBP1 gene PMID: 27578123
  9. mAbs RE3 and RG3 bound with reduced affinity to a mutant GPIHBP1 containing an Ly6 domain mutation (W109S) that abolishes LPL binding. Immunohistochemistry studies with the GPIHBP1 mAbs revealed that human GPIHBP1 is expressed only in capillary endothelial cells. Finally, we created an ELISA that detects GPIHBP1 in human plasma. PMID: 27875259
  10. The binding of both antibody 88B8 and GPIHBP1 to LPL depends on large segments of LPL's carboxyl-terminal domain. PMID: 27494936
  11. An LPL structural model suggests that the LPL S447X truncation exposes residues implicated in LPL binding to lipoprotein binding uptake receptors, such as GPIHBP1. PMID: 27984852
  12. The acidic domain of GPIHBP1 stabilizes LPL catalytic activity by mitigating the global unfolding of LPL's catalytic domain. PMID: 26725083
  13. 2 novel GPIHBP1 missense mutations in 2 unrelated patients as the cause of their severe hypertriglyceridemia PMID: 26892125
  14. GPIHBP1 mutations should be considered in neonates with chylomicronemia negative for mutations in LPL gene PMID: 25911085
  15. the two domains of GPIHBP1 interact independently with LPL and the functionality of LPL depends on its localization on GPIHBP1 PMID: 25873395
  16. No GPIHBP1 mutations were identified in a cohort of patients with diabetic lipemia. PMID: 25131724
  17. patient with type I hyperlipoproteinemia harbored homozygous mutation in case series PMID: 24793350
  18. GPIHBP1 missense mutations leading to protein multimerization prevent lipoprotein lipase binding. PMID: 25387803
  19. Homozygosity for a deletion of exons 3 and 4 of GPIHBP1 results in Type 1 hyperlipoproteinemia. PMID: 24589565
  20. an extra cysteine in the GPIHBP1 Ly6 motif results in multimerization of GPIHBP1, defective LPL binding, and severe hypertriglyceridemia. PMID: 24847059
  21. Wild-type lipoprotein lipase (LPL) and a mutated (S447X-LPL) protein bind to the endothelial cell LPL transporter GPIHBP1 with equal efficiency. PMID: 24704550
  22. A polymorphism in the GPIHBP1 gene promoter was associated with an increased risk of hypertriglyceridemia and had an additive effect on the risk conferred by LPL defective alleles. PMID: 21978733
  23. Mutations in GPIHBP1 are rare but the associated clinical phenotype of hypertriglyceridaemia is severe. PMID: 22239554
  24. analysis of a neonate with complete GPIHBP1 deficiency due to homozygosity for a deletion of GPIHBP1 [case report] PMID: 22008945
  25. Expression of glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 tended to be higher in young healthy subjects than in subjects with type 2 diabetes mellitus or Colder control subjects PMID: 22078753
  26. function and genetics of GPIHBP1 in lipoprotein lipase transport PMID: 21844202
  27. we first report a mutation of the hydrophobic C-terminal domain that impairs GPIHBP1 membrane targeting PMID: 21816778
  28. Findings provide further evidence that GPIHBP1 is involved in the catabolism of triglyceride-rich lipoproteins and plays a role in childhood-onset chylomicronaemia. PMID: 21314738
  29. the Ly6 domain of GPIHBP1 is important for the ability of GPIHBP1 to bind and transport LPL. PMID: 21478160
  30. report that two LPL missense mutations initially identified in patients with chylomicronemia, C418Y and E421K, abolish LPL's ability to bind to GPIHBP1 without interfering with LPL catalytic activity or binding to heparin PMID: 21518912
  31. GPIHBP1 binds lipoprotein lipase but does not bind other lipase family members. GPIHBP1 binds apoAV but does not bind apoAI or high-density lipoprotein. GPIHBP1 binding to chylomicrons is mediated by lipoprotein lipase. PMID: 20966398
  32. The conserved cysteines in the Ly6 domain are crucial for GPIHBP1 function. PMID: 20026666
  33. Observational study of gene-disease association. (HuGE Navigator) PMID: 20237496
  34. GPIHBP1 functions as an LPL stabilizer PMID: 19542565
  35. a very rare GPIHBP1 missense mutation appears to be associated with severe hypertriglyceridemia and chylomicronemia. PMID: 17883852
  36. Data show that the G56R substitution did not affect the ability of GPIHBP1 to reach the cell surface, nor did the amino acid substitution have any discernible effect on the binding of lipoprotein lipase, chylomicrons, or apo-AV. PMID: 17997385
  37. the acidic domain of GPIHBP1 is important and electrostatic interactions play a key role in ligand binding PMID: 18713736
  38. Case Report: Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. PMID: 19304573

Show More

Hide All

Involvement in disease
Hyperlipoproteinemia 1D (HLPP1D)
Subcellular Location
Apical cell membrane; Lipid-anchor, GPI-anchor. Basolateral cell membrane; Lipid-anchor, GPI-anchor. Cell membrane; Lipid-anchor, GPI-anchor.
Database Links

HGNC: 24945

OMIM: 612757

KEGG: hsa:338328

STRING: 9606.ENSP00000329266

UniGene: Hs.426410

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*